Fibrocell Science, Inc. and Top University Investigators Form Scientific Initiative to Assist in Securing Grant Funding for Research to Advance the Development of Personalized Cell Therapies  
5/15/2012 10:05:44 AM

EXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (OTCBB:FCSC.OB) announced today the formation of the Clinical Investigations for Dermal Mesenchymally-Obtained Derivatives (CIDMOD) Initiative ( in collaboration with researchers from a number of different universities across the U.S. The CIDMOD Initiative will facilitate the collaboration of scientists, clinical researchers and private entities, including Fibrocell, to secure funding that will advance clinical research programs that may one day lead to new personalized cell therapies or diagnostic tools for a variety of diseases and conditions. The group will also submit grant requests to the California Institute of Regenerative Medicine (CIRM) and seek additional funding for the development of clinical research programs that use Fibrocell’s deep knowledge and expertise in cell isolation, purification and expansion via use of its proprietary technology.